Podcasts about genome sciences

In this program, Dr. Jeffrey Gordon, Director of the Edison Family Center for Genome Sciences & Systems Biology at Washington University and the Scripps Institution of Oceanography's 2024 recipient of the Nierenberg Prize for Science in the Public Interest, discusses his research into the microbiome. Gordon is credited with founding the field of gut microbiome research. His transformative studies have demonstrated that human health and disease are shaped by the communities of microbes that live in the human gut. His body of work has opened up the vast new therapeutic potential for the microbiome, exemplified by his identification of ways to repair the gut microbiomes of children with malnutrition and restore their healthy growth. Series: "Science in the Public Interest" [Health and Medicine] [Show ID: 40154]

In this program, Dr. Jeffrey Gordon, Director of the Edison Family Center for Genome Sciences & Systems Biology at Washington University and the Scripps Institution of Oceanography's 2024 recipient of the Nierenberg Prize for Science in the Public Interest, discusses his research into the microbiome. Gordon is credited with founding the field of gut microbiome research. His transformative studies have demonstrated that human health and disease are shaped by the communities of microbes that live in the human gut. His body of work has opened up the vast new therapeutic potential for the microbiome, exemplified by his identification of ways to repair the gut microbiomes of children with malnutrition and restore their healthy growth. Series: "Science in the Public Interest" [Health and Medicine] [Show ID: 40154]

In this program, Dr. Jeffrey Gordon, Director of the Edison Family Center for Genome Sciences & Systems Biology at Washington University and the Scripps Institution of Oceanography's 2024 recipient of the Nierenberg Prize for Science in the Public Interest, discusses his research into the microbiome. Gordon is credited with founding the field of gut microbiome research. His transformative studies have demonstrated that human health and disease are shaped by the communities of microbes that live in the human gut. His body of work has opened up the vast new therapeutic potential for the microbiome, exemplified by his identification of ways to repair the gut microbiomes of children with malnutrition and restore their healthy growth. Series: "Science in the Public Interest" [Health and Medicine] [Show ID: 40154]

In this program, Dr. Jeffrey Gordon, Director of the Edison Family Center for Genome Sciences & Systems Biology at Washington University and the Scripps Institution of Oceanography's 2024 recipient of the Nierenberg Prize for Science in the Public Interest, discusses his research into the microbiome. Gordon is credited with founding the field of gut microbiome research. His transformative studies have demonstrated that human health and disease are shaped by the communities of microbes that live in the human gut. His body of work has opened up the vast new therapeutic potential for the microbiome, exemplified by his identification of ways to repair the gut microbiomes of children with malnutrition and restore their healthy growth. Series: "Science in the Public Interest" [Health and Medicine] [Show ID: 40154]

In this program, Dr. Jeffrey Gordon, Director of the Edison Family Center for Genome Sciences & Systems Biology at Washington University and the Scripps Institution of Oceanography's 2024 recipient of the Nierenberg Prize for Science in the Public Interest, discusses his research into the microbiome. Gordon is credited with founding the field of gut microbiome research. His transformative studies have demonstrated that human health and disease are shaped by the communities of microbes that live in the human gut. His body of work has opened up the vast new therapeutic potential for the microbiome, exemplified by his identification of ways to repair the gut microbiomes of children with malnutrition and restore their healthy growth. Series: "Science in the Public Interest" [Health and Medicine] [Show ID: 40154]

Send us a Text Message.Dr. Eliah Overbey, Ph.D. is Assistant Professor of Bioastronautics at The University of Austin ( UATX - https://www.uaustin.org/people/eliah-overbey ) where she is involved in pioneering research in the field of astronaut health, specializing in spaceflight-induced genomic changes. Her work focuses on mapping changes in the human body during spaceflight and developing Earth-independent laboratories to make humans a multi-planetary species ( https://www.eliahoverbey.com/ ). Dr. Overbey comes to UATX from her previous position as a Research Associate at Weill Cornell Medicine. Dr. Overbey's most recent projects have analyzed genomic changes in astronauts from the SpaceX Inspiration4 mission, and she is currently working on data analysis and sample collection for the Axiom-2 and Polaris Dawn missions. Dr. Overbey's work launched the Space Omics and Medical Atlas ( SOMA - https://soma.weill.cornell.edu/#main ), an online portal with the largest compendium of molecular measurements from astronauts. She also serves as Vice Chair of the Cornell Aerospace Medicine Biobank ( CAMbank - https://cambank.weill.cornell.edu/#main ), which is the first biorepository of samples from commercial astronauts. Dr. Overbey is also Chief Scientific Officer at BioAstra ( https://www.bioastra.org/ ), a non-profit developing healthcare systems for astronauts. Dr. Overbey received a B.S. in Computer Science from UC San Diego, a Ph.D. in Genome Sciences from the University of Washington, and was a Postdoctoral Associate in Computational Biomedicine in the laboratory of Dr. Christopher Mason. Support the Show.

Dr. Riddhiman Garge, post-doctoral researcher at the University of Washington in the Department of Genome Sciences, joins Cade in the lab this week to discuss his work on how brewer's yeast responds to the evolutionary pressures of fermentation and serial re-pitching. The Brü Lab is brought to you by Imperial Yeast who provide brewers with the most viable and fresh yeast on the market. Learn more about what Imperial Yeast has to offer at ImperialYeast.com today. | Read More | Systematic Profiling of Ale Yeast Protein Dynamics across Fermentation and Repitching Proteomic profiling of Hefeweizen ale yeast across fermentation and repitching

Dr. Berkley Gryder, Assistant Professor, Department of Genetics and Genome Sciences, School of Medicine, is a chemist who retrained as a molecular biologist and computer scientist. He's here to school the Ravel-rowdy-boys on what, exactly, is going on in our bodies! From quadraplexes, telemeres, and DNA sequencing - to - Scientific consensus, cancer research, and transhumanism, Dr. Berkley Gryder is here to bring that sweet science sauce to this Ravel casserole! (Sorry, still working through the thanksgiving left-overs) https://gryderlab.com/ https://twitter.com/gryderart

That's a wrap! Season 12 of the One Percent Podcast is now on all podcast platforms.   We pulled together a recap episode for you this week, featuring short clips from some of the great moments in the podcast's twelfth season. We were fortunate to have incredible leaders from across industries, disciplines, and fields share their stories and perspectives – and we wanted to share them with you as we wrap up Season 12 and look ahead to the next season.   Here are some of the guests featured in this wrap-up episode:   Jeffrey Pfeffer: American business theorist, university professor, social scientist, and author  Carl Honoré: award-winning writer, broadcaster, TED speaker, Ageism Disruptor, and voice of the global Slow Movement Deirdre O'Shea: Associate Professor of Work and Organisational Psychology at the University of Limerick, a Fellow of the Psychological Society of Ireland and Chartered Work and Organizational Psychologist (I/O Psychologist) Matt Johnson: speaker, researcher, and writer specializing in the application of psychology and neuroscience to marketing Matt Kaeberlein: Professor of Pathology, Adjunct Professor of Genome Sciences, and Adjunct Professor of Oral Health Sciences at the University of Washington   We're hard at work planning Season 13, and as always we would love your feedback and perspective.

Through its Citation Laureates program, Clarivate recognises individuals whose research publications are highly cited and whose contributions to their fields have been extremely influential, even transformative. This year, we named twenty world-class researchers from four countries as Citation Laureates. These are researchers whose work is deemed to be ‘of Nobel class', as demonstrated by analysis carried out by the ISI, and who are in the running for future Nobel honours. In this episode, you'll hear from two of this year's Citation Laureates who share insights into their work, how they got started, tips for young researchers, and more - Mary-Claire King, Professor of Medicine and of Genome Sciences, School of Medicine, at the University of Washington in Seattle, in the United States, recognized for demonstrating inherited susceptibility for breast and ovarian cancer and discovering the role played by mutations of the BRCA1 gene and Zhenan Bao, the K.K. Lee Professor of Chemical Engineering, and Director, Stanford Wearable Electronics Initiative (eWEAR), at Stanford University, California, recognized for the development of novel biomimetic applications of organic and polymeric electronic materials, including flexible ‘electronic skin.' Hosted on Acast. See acast.com/privacy for more information.

Dr Matt Kaeberlein is a Professor of Pathology, Adjunct Professor of Genome Sciences, and Adjunct Professor of Oral Health Sciences at the University of Washington. His research is focused on the basic mechanisms of aging in order to facilitate translational interventions that promote healthspan and improve quality of life.    Dr. Kaeberlein is also a co-director of the Dog Aging Project, in Washington, which is investigating the use of rapamycin as an intervention to enhance canine longevity.

We know that some of our Audacious episodes, well, they can be kinda heavy. So for our 100th episode, it's all about GOOD NEWS! You'll hear about a baby announcement, an upcoming wedding, and a big grant approval. Plus, a powerful compliment, an important anniversary, a surprising acceptance at a funeral, and even what it's like to find out that you just won a year's worth of free smoothies! GUESTS:  Alexa La Fever, Empress of Tease: Burlesque teacher based in Hartford, CT Coleman Gladis: Filmmaker, composer, and Chion's cousin, based in Malvern, PA Dr. Brenton Graveley: Professor and Chair of Genetics and Genome Sciences at University of Connecticut Health Center. He runs the Graveley Lab, which studies RNA Andre Rochester: Fine artist, curator, art advocate and administrator living in East Hartford Karleigh Webb: Journalist and co-host of the podcast, The Trans Sporter Room. She is based out of New Britain, CT Katie Blanchard & Amy Radzvilowicz: Newly-engaged couple based out of New London, CT Nina & Nicole Jackman: Couple celebrating 10 years together, living and raising their family in central Connecticut Support the show: https://www.wnpr.org/donateSee omnystudio.com/listener for privacy information.

The Life-Extension Episode — Dr. Matt Kaeberlein on The Dog Aging Project, Rapamycin, Metformin, Spermidine, NAD+ Precursors, Urolithin A, Acarbose, and Much More | Brought to you by Levels real-time feedback on how diet impacts your health, Athletic Greens all-in-one nutritional supplement, and LMNT electrolyte supplement. More on all three below.Dr. Matt Kaeberlein (@mkaeberlein) is a professor of Laboratory Medicine and Pathology at the University of Washington School of Medicine, with adjunct appointments in Genome Sciences and Oral Health Sciences. Dr. Kaeberlein's research interests are focused on understanding biological mechanisms of aging in order to facilitate translational interventions that promote healthspan and improve quality of life for people and companion animals.Dr. Kaeberlein is the founding director of the University of Washington Healthy Aging and Longevity Research Institute, the director of the NIH Nathan Shock Center of Excellence in the Basic Biology of Aging at University of Washington, director of the Biological Mechanisms of Healthy Aging Training Program, and founder and co-director of the Dog Aging Project.Please enjoy!This episode is brought to you by Athletic Greens. I get asked all the time, “If you could use only one supplement, what would it be?” My answer is usually AG1 by Athletic Greens, my all-in-one nutritional insurance. I recommended it in The 4-Hour Body in 2010 and did not get paid to do so. I do my best with nutrient-dense meals, of course, but AG further covers my bases with vitamins, minerals, and whole-food-sourced micronutrients that support gut health and the immune system. Right now, Athletic Greens is offering you their Vitamin D Liquid Formula free with your first subscription purchase—a vital nutrient for a strong immune system and strong bones. Visit AthleticGreens.com/Tim to claim this special offer today and receive the free Vitamin D Liquid Formula (and five free travel packs) with your first subscription purchase! That's up to a one-year supply of Vitamin D as added value when you try their delicious and comprehensive all-in-one daily greens product.*This episode is also brought to you by LMNT! What is LMNT? It's a delicious, sugar-free electrolyte drink mix. I've stocked up on boxes and boxes of this and usually use it 1–2 times per day. LMNT is formulated to help anyone with their electrolyte needs and perfectly suited to folks following a keto, low-carb, or Paleo diet. If you are on a low-carb diet or fasting, electrolytes play a key role in relieving hunger, cramps, headaches, tiredness, and dizziness.LMNT came up with a very special offer for you, my dear listeners. For a limited time, you can get a free LMNT Sample Pack with any purchase. This special offer is available here: DrinkLMNT.com/Tim.*This episode is also brought to you by Levels! I wrote about the health benefits of using continuous glucose monitors (CGMs) more than ten years ago in The 4-Hour Body. At the time, CGMs were primitive and hard to use. Levels has now made this technology, and the unique insights that come from it, easy and available to everyone. Levels is making glucose monitoring simple, helping you see how food affects your health through real-time feedback. I started tracking my glucose years ago to learn more about what I should and shouldn't be eating (including quantities, time of day, etc.), based on objective data from my own, unique physiology. Keeping my blood sugar stable is critical to my daily and long-term health and performance goals. Furthermore, poor glucose control is associated with a number of chronic conditions like diabetes, Alzheimer's disease, heart disease, and obesity. It's important.If you're interested in learning more about Levels and trying a CGM yourself, go to Levels.link/Tim.*For show notes and past guests on The Tim Ferriss Show, please visit tim.blog/podcast.For deals from sponsors of The Tim Ferriss Show, please visit tim.blog/podcast-sponsorsSign up for Tim's email newsletter (5-Bullet Friday) at tim.blog/friday.For transcripts of episodes, go to tim.blog/transcripts.Discover Tim's books: tim.blog/books.Follow Tim:Twitter: twitter.com/tferriss Instagram: instagram.com/timferrissYouTube: youtube.com/timferrissFacebook: facebook.com/timferriss LinkedIn: linkedin.com/in/timferrissPast guests on The Tim Ferriss Show include Jerry Seinfeld, Hugh Jackman, Dr. Jane Goodall, LeBron James, Kevin Hart, Doris Kearns Goodwin, Jamie Foxx, Matthew McConaughey, Esther Perel, Elizabeth Gilbert, Terry Crews, Sia, Yuval Noah Harari, Malcolm Gladwell, Madeleine Albright, Cheryl Strayed, Jim Collins, Mary Karr, Maria Popova, Sam Harris, Michael Phelps, Bob Iger, Edward Norton, Arnold Schwarzenegger, Neil Strauss, Ken Burns, Maria Sharapova, Marc Andreessen, Neil Gaiman, Neil de Grasse Tyson, Jocko Willink, Daniel Ek, Kelly Slater, Dr. Peter Attia, Seth Godin, Howard Marks, Dr. Brené Brown, Eric Schmidt, Michael Lewis, Joe Gebbia, Michael Pollan, Dr. Jordan Peterson, Vince Vaughn, Brian Koppelman, Ramit Sethi, Dax Shepard, Tony Robbins, Jim Dethmer, Dan Harris, Ray Dalio, Naval Ravikant, Vitalik Buterin, Elizabeth Lesser, Amanda Palmer, Katie Haun, Sir Richard Branson, Chuck Palahniuk, Arianna Huffington, Reid Hoffman, Bill Burr, Whitney Cummings, Rick Rubin, Dr. Vivek Murthy, Darren Aronofsky, and many more.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In response to several requests from listeners, we have as our guest today, Dr. Matt Kaeberlein, a professor of pathology at the University of Washington. Matt is well-known for his investigations into the basic mechanisms of aging. Much of his research in this area is focused on identifying interventions that promote healthspan and lifespan. In today's interview, we talk to Matt about the biology of aging and what he has learned about slowing the aging process.  In 1999, Matt and his colleague Mitch McVey discovered that overexpression of the SIR2 gene is sufficient to extend lifespan in yeast. SIR stands for silent information regulator, and we have an interesting discussion about how Matt's research and 1999 discovery have elevated SIR2 to the forefront of aging research. Also, some of Matt's most recent and fascinating investigations have been into rapamycin, the only known pharmacological agent to extend lifespan.  His research has shed new light on the role rapamycin plays in delaying age-related dysfunction in rodents, dogs, and humans. We also have a fun discussion with Matt about his research showing that rapamycin may have the potential to reduce the mortality of companion dogs. The paper that came out of this research landed Matt on the front page of the New York Times and received prominent play in the national and overseas media. Other topics we cover include: Matt's attempts to uncover the molecular mechanism behind lifespan extension via calorie restriction. His research into mTOR, which is a protein in every cell, and how inhibiting mTOR has been shown to extend the lifespan of insects, rodents, and animals. Matt's 2006 study that showed fasting extends lifespan in worms more than caloric restriction. And an article Matt published last year that summarized several of the most popular anti-aging diets, comparing them with classical caloric restriction. In addition to his work in his Kaeberlein Lab, Matt is the co-director of the Nathan Shock Center of Excellence in the Basic Biology of Aging and the founding director of the Healthy Aging and Longevity Research Institute at the University of Washington. He also is the founder and co-director of the Dog Aging Project. Show notes: [00:02:53] Dawn asks Matt and his youth and where he grew up. [00:03:06] Ken asks if it is true that Matt spent a good deal of his youth “up to no good.” [00:04:20] Dawn mentions that while Matt got decent grades in school, it wasn't until he went to college that he became studious. Dawn asks Matt if it true that he had originally decided to skip college. [00:05:42] Dawn asks how Matt ended up in Bellingham at Western Washington. [00:06:41] Dawn asks how in the world, despite not liking high school and working a morning shift at UPS for two years after graduating, Matt decided to head off for college and major in biochemistry of all things. [00:08:01] Ken asks what led Matt to travel across the country to Boston and MIT's biology program. [00:09:57] Ken asks why Matt decided to focus his research on the biology of aging. [00:11:57] Matt talks about what he did following his Ph.D. [00:13:15] Dawn asks Matt what kind of research he did at the University of Washington Department of Genome Sciences for his post-doc, and how this research related to aging. [00:15:10] Ken mentions that it was during Matt's undergrad that he decided to focus on the question, “To what extent are the mechanisms of aging evolutionarily conserved?” Ken asks Matt what caused him to arrive at that for his central focus. [00:19:36] Dawn mentions that the discovery by Matt, and Mitch McVey, that overexpression of SIR2 (Silent Information Regulator) is sufficient to extend life span in yeast is credited with promoting SIR2 to the forefront of aging research. Dawn goes on to mention that SIR genes are determinants of life span in yeast mother cells. Dawn asks Matt to give a quick primer on the SIR genes a...

Very few of us can say that our careers span continents, species, and millennia but Brandi Cantarel, Associate Director of Bioinformatics at Colossal Biosciences, can. For over 15 years, Brandi has been involved in projects that utilize sequence technology to understand human health, often at the forefront of an emerging field or technology. She leads bioinformatics development of next-generation sequence (NGS) data, including genomics, transcriptomics, and metagenomics in rare/complex genetic diseases, immunology, infectious disease, and cancer. She has applied precision medicine research in a CAP/CLIA setting, with the development of tools for tumor mutational profiling. Prior, Brandi was a faculty member at the UT Southwestern Medical Center, Department of Bioinformatics, and at the University of Maryland, Institute for Genome Sciences. In 2020, Brandi was named a Highly Cited Researcher by Web of Science. In today's episode, we talk about academia from a non-tenure-track perspective, working towards creating a mammoth-elephant hybrid animal, and the nontraditional and awesome ways that biotech startups tackle critical problems with global impact like fighting climate change. (Hint: We say screw it, let's bring back the mammoth and see what works.) Her advice for our listeners? Focus on the science, raise your voice when you feel like it's being done incorrectly, and hire people that are better than you and let them shine. And always be kind to people. We hope you enjoy this conversation as much as we did! *Disclaimer (27:15): The oldest sequencable DNA is 1M year old, not 10K years old. This is not as far back at the mass extinction of dinosaurs (~66 million years).

Join us as we discuss the vaginal microbiome. Jacques explains what it is, how to support it, and what to stop doing so that you can continue to have a healthy vaginal microbiota. This is a fascinating conversation that reveals so much about what we know so far and what we have yet to learn in this unique microbiome.  Some background on Dr. Jacques Ravel, he is a professor in the Department of Microbiology and Immunology, and the Associate Director for Genomics at The Institute for Genome Sciences, University of Maryland, School of Medicine in Baltimore Maryland. Over the past 15 years, he has developed a research program focused on applying modern genomic technologies and ecological principles to characterize the role and dynamics of the microbial communities inhabiting the human body in health and disease and better define the interactions between the host, the microbes and the environment that drives these ecological systems. Specifically, he is interested in the role of the vaginal microbiome in women's health in order to develop improved strategies to manage gynecological and obstetrics conditions. He has published over 225 peer-reviewed publications and has attracted grant income of more than $30 million. His work is currently being translated by developing novel live microbiome-based biotherapeutic formulations targeted to restore vaginal health, treat conditions such as bacterial vaginosis, urinary tract infections and improved fertility. His work earned him to be elected to the fellowship of the American Academy of Microbiology, and in 2015, he was awarded the Blaise Pascal international research chair. He is the founder and editor-in-chief of the journal Microbiome. He joined the Institute for Genome Sciences at The University of Maryland Medical School in 2007 as an associate professor. To learn more about  Dr. Jacques Ravel click here. Episode Takeaways: What is the vaginal microbiome? The vaginal microbiome is just like the gut, it's a collection of bacteria that live together to perform a function that is beneficial. If it lives in the body, it's often beneficial to the host. When it comes to the vaginal microbiota, there are five types of women, four of these types are dominated by lactobacillus, one of the four species (lactobacillus crispatus, lactobacillus iners, lactobacillus gasseri, lactobacillus jensenii). And one of them is not and it's represented, it's more like the gut, this type is very diverse. So you can see it's diverse and very even, a lot more even than what you see in the others. Those bacteria, they acidify the vagina, the pH of the vagina is about 3.6-4, so it's very acidic Those that have an acidified environment are those that you would call very well-protected 25-30% of women that don't have lactobacillus How does the composition of the vaginal microbiome impact a woman's overall health? Without a healthy vaginal microbiome, women are subject to many different risks Sexually transmitted infections A woman being able to get pregnant - the implantation of the egg Chronic yeast infections Vaginal dryness which can make intercourse very painful Can lubricants affect the vaginal microbiome negatively? They are very hypertonic, that's a big problem because what happens is it dries the cells Most lubricants, especially in medicine, contain antimicrobial agents, so it kills even the good bacteria Not every woman is affected by the application of lubricant What are some of the things that people are doing in day to day life that seem to be hurting the vaginal microbiome? Douching - you're basically washing your vagina with chemicals Smoking has a major impact on the vaginal microbiota Poor diet A really heavy dose of azithromycin has a really detrimental effect on the vaginal microbiota What can women start doing right now to help support a healthy vaginal microbiome? Eat healthy - whole foods, less packaged food No smoking Some studies show that exercise helps support a healthy vagina as well Where to learn more about Dr. Jacques Ravel,  Website: http://ravel-lab.org Youtube: https://www.youtube.com/watch?v=UEQ5hVUYOtg Connect with Kiran and Dr. Nicole: Website: BetterBiome.com Instagram: better.biome Instagram: Microbiome Keynotes Facebook: Microbiome Keynotes Instagram: Dr. Nicole Instagram: Kiran Krishnan

Dr. Matt Kaeberlein is a Professor of Pathology, Adjunct Professor of Genome Sciences, and Adjunct Professor of Oral Health Sciences at the University of Washington. His research interests are focused on basic mechanisms of aging in order to facilitate translational interventions that promote healthspan and improve quality of life. Matt has been around the field of aging for a long time and knows more about the work in the aging field than perhaps anyone else. This was a comprehensive conversation where we spoke about how Matt thinks of aging from a functional perspective, caloric restriction and aging, whether NAD+ precursors are effective in slowing aging, the role of sirtuins. We discuss quite a bit on rapamycin and how it's shown to be effective in improving the health of mice. Matt is very excited about the potential benefits of Rapamycin in reversing aging and he got me excited too. Matt is also working on the Dog Aging project and in trying to understand aging in dogs. Finally, we end the conversation by talking a bit on what good scientific practices should look like. Matt approaches his work with an unbiased lens and that's very respectable. Matt has a brilliant mind! I had such a blast talking to Matt and I hope you enjoy the conversation as much as I did! Timestamps in the YouTube version of this podcast: ttps://www.youtube.com/channel/UCcoEB1MXhkI_CFwsHRtPXUg FOLLOW LIVE LONGER WORLD: Twitter: https://twitter.com/livelongerworld Website: https://www.livelongerworld.com/ YouTube: https://www.youtube.com/channel/UCcoEB1MXhkI_CFwsHRtPXUg Patreon: https://www.patreon.com/livelongerworld Apple Podcasts: https://podcasts.apple.com/us/podcast/live-longer-world/id1588806541 Spotify: https://open.spotify.com/show/2Zc65BZb02msGuF9ujBThC Instagram: https://www.instagram.com/longevityfuture/ Store: https://www.longevitystore.co/ FOLLOW MATT KAEBERLIN: Website: https://kaeberlein.org/ Twitter: https://twitter.com/mkaeberlein Dog Aging Project: https://dogagingproject.org/

Our Human Variability is a comprehensive book based on an in-depth filmed conversation between Howard Burton and Stephen Scherer, the GlaxoSmithKline Research Chair in Genome Sciences at the Hospital for Sick Children and University of Toronto. Stephen Scherer discusses his lifelong passion for science that culminated in his groundbreaking discovery of copy-number variation. This conversation also covers his exciting work in autism research and how copy number variation brings us a deeper understanding of both human variability and disease. Howard Burton is the founder of the Ideas Roadshow, Ideas on Film and host of the Ideas Roadshow Podcast. He can be reached at howard@ideasroadshow.com. Learn more about your ad choices. Visit megaphone.fm/adchoices

Our Human Variability is a comprehensive book based on an in-depth filmed conversation between Howard Burton and Stephen Scherer, the GlaxoSmithKline Research Chair in Genome Sciences at the Hospital for Sick Children and University of Toronto. Stephen Scherer discusses his lifelong passion for science that culminated in his groundbreaking discovery of copy-number variation. This conversation also covers his exciting work in autism research and how copy number variation brings us a deeper understanding of both human variability and disease. Howard Burton is the founder of the Ideas Roadshow, Ideas on Film and host of the Ideas Roadshow Podcast. He can be reached at howard@ideasroadshow.com. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/medicine

Our Human Variability is a comprehensive book based on an in-depth filmed conversation between Howard Burton and Stephen Scherer, the GlaxoSmithKline Research Chair in Genome Sciences at the Hospital for Sick Children and University of Toronto. Stephen Scherer discusses his lifelong passion for science that culminated in his groundbreaking discovery of copy-number variation. This conversation also covers his exciting work in autism research and how copy number variation brings us a deeper understanding of both human variability and disease. Howard Burton is the founder of the Ideas Roadshow, Ideas on Film and host of the Ideas Roadshow Podcast. He can be reached at howard@ideasroadshow.com. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/science-technology-and-society

Our Human Variability is a comprehensive book based on an in-depth filmed conversation between Howard Burton and Stephen Scherer, the GlaxoSmithKline Research Chair in Genome Sciences at the Hospital for Sick Children and University of Toronto. Stephen Scherer discusses his lifelong passion for science that culminated in his groundbreaking discovery of copy-number variation. This conversation also covers his exciting work in autism research and how copy number variation brings us a deeper understanding of both human variability and disease. Howard Burton is the founder of the Ideas Roadshow, Ideas on Film and host of the Ideas Roadshow Podcast. He can be reached at howard@ideasroadshow.com. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/science

Our Human Variability is a comprehensive book based on an in-depth filmed conversation between Howard Burton and Stephen Scherer, the GlaxoSmithKline Research Chair in Genome Sciences at the Hospital for Sick Children and University of Toronto. Stephen Scherer discusses his lifelong passion for science that culminated in his groundbreaking discovery of copy-number variation. This conversation also covers his exciting work in autism research and how copy number variation brings us a deeper understanding of both human variability and disease. Howard Burton is the founder of the Ideas Roadshow, Ideas on Film and host of the Ideas Roadshow Podcast. He can be reached at howard@ideasroadshow.com. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/new-books-network

 Dr. Matt Kaeberlein is Professor of Pathology, Adjunct Professor of Genome Sciences, and Adjunct Professor of Oral Health Sciences, at the University of Washington. Dr. Kaeberlein received his PhD from MIT in Biology, did his post-doc in the Department of Genome Sciences, University of Washington, and his research interests are focused on basic mechanisms of aging in order to facilitate translational interventions that promote healthspan and improve quality of life. Dr. Kaeberlein has published nearly 200 papers in top scientific journals and has been recognized by several prestigious awards, including a Breakthroughs in Gerontology Award, an Alzheimer's Association Young Investigator Award, an Ellison Medical Foundation New Scholar in Aging Award, a Murdock Trust Award, a Pioneer in Aging Award, and the Vincent Cristofalo Rising Star in Aging Research. Dr. Kaeberlein's contributions have also been recognized with Fellow status in the American Association for the Advancement of Science, the American Aging Association, and the Gerontological Society of America. Dr. Kaeberlein is a past President of the American Aging Association and has served on their Executive Committee and Board of Directors since 2012. He has also served as a member of the Board of Directors for the Federation of American Societies for Experimental Biology and is currently the Chair of the Biological Sciences Section of the Gerontological Society of America. Dr. Kaeberlein serves on the editorial boards for several journals, including Science and eLife. Dr. Kaeberlein's scientific discoveries have generated substantial public interest, with featured stories in major media outlets including appearing on the front page of the New York Times, the Today Show, CNN, the UK Telegraph, Popular Science, Time Magazine, Scientific American, NPR, USA Today, National Geographic, and many others. In addition to his primary appointments, Dr. Kaeberlein is the co-Director of the University of Washington Nathan Shock Center of Excellence in the Basic Biology of Aging, the Founding Director of the Healthy Aging and Longevity Research Institute at the University of Washington, and Founder and Co-Director of the Dog Aging Project. 

Prader-Willi Syndrome is a rare genetic neurodevelopmental disorder that gives rise to a vast array of symptoms which affect the individual from birth. There is currently no cure for Prader-Willi Syndrome. Professor Gordon Carmichael and his team from the Department of Genetics and Genome Sciences at the University of Connecticut Health Centre, USA, believe it is crucial to understand the affected chromosome 15 region to unravel the pathogenesis of Prader-Willi Syndrome and his team are making significant strides towards achieving this goal.

On Episode 7 of Rosé and DNA, we got to hang out with Robin Aguilar! Robin is a PhD Candidate in the Department of Genome Sciences at the University of Washington in Seattle, where they are an NSF Fellow (impressive). Robin's research focuses on creating tools and technologies to image satellite DNA. We had the pleasure of connecting with Robin after reading their incredibly important Career Column in Nature: https://www.nature.com/articles/d41586-021-00521-1 As a first-generation, queer, non-binary, and disabled scientist, a lot of Robin's work outside of the lab focuses on providing support and connection for folks of marginalized identities in and out of STEM. They also are an artist and writer. To learn more about their work, art, and mission, check out their website at robinaguilar.com! Causes Robin cares about: Lambert House El Centro de la Raza yəhaw̓ Ingersoll Gender Center Homeless Black Trans Women Fund Wines tasted (and talked about!): Mojave Rain - 2016 red blend from Paso Robles A. Golden & Fils Rosé Cheers! R&D

Professor Kaeberlein talks about the work that his lab is doing and how he views aging in this video. He also touches on how the message is being more widely received, Dr. Matt Kaeberlein is a Professor of Pathology, Adjunct Professor of Genome Sciences, and Adjunct Professor of Oral Health Sciences at the University of Washington. His research interests are focused on basic mechanisms of aging in order to facilitate translational interventions that promote healthspan and improve quality of life. He is currently leading The Dog Aging project, a large multi-year trial to study the aging of companion dogs in a normal environment. He has published nearly 200 papers in top scientific journals and has been recognized by several prestigious awards, including a Breakthroughs in Gerontology Award, and most recent GSA's 2020 Robert W. Kleemeier Award Professor Kaeberlein at University of Washington https://depts.washington.edu/mbwc/about/profile/matt-kaeberlein Dog Aging Project. https://dogagingproject.zendesk.com/hc/en-us

In this show, we had the pleasure of speaking with Steve Henikoff who studies chromosomes, chromatin dynamics and epigenetics and develops genomics and computational tools to facilitate this research. He received a BS from the University of Chicago and a PhD from Harvard University and did post-doctoral work at the University of Washington. He has been a faculty member of the Fred Hutchinson Cancer Research Center since 1981. He is also an investigator of the Howard Hughes Medical Institute, an affiliate professor of Genome Sciences at the University of Washington, a member of the National Academy of Sciences and co-Editor-in-Chief of the open access journal Epigenetics & Chromatin. In this episode we're talking with Steve about his work, his approach to method development and refinement, and more. Links: Steven Henikoff protocols.io publications - https://www.protocols.io/researchers/steven-henikoff/protocols Human Cell Atlas - https://www.humancellatlas.org/ CUT&Tag@home was recently chosen by the The Scientist as one of the top 5 technical advances of 2020 - https://www.the-scientist.com/news-opinion/top-technical-advances-of-2020-68297 CUT&Tag@home - https://dx.doi.org/10.17504/protocols.io.bmbfk2jn eLife article ‘Efficient chromatin accessibility mapping in situ by nucleosome-tethered tagmentation‘ - https://doi.org/10.7554/eLife.63274 Jim Watson's book “Molecular Biology of the Gene” - https://www.amazon.com/Molecular-Biology-Fifth-James-Watson/dp/080534635X NIH ENCODE Project - https://www.genome.gov/Funded-Programs-Projects/ENCODE-Project-ENCyclopedia-Of-DNA-Elements

In this show, we had the pleasure of speaking with Steve Henikoff who studies chromosomes, chromatin dynamics and epigenetics and develops genomics and computational tools to facilitate this research. He received a BS from the University of Chicago and a PhD from Harvard University and did post-doctoral work at the University of Washington. He has been a faculty member of the Fred Hutchinson Cancer Research Center since 1981. He is also an investigator of the Howard Hughes Medical Institute, an affiliate professor of Genome Sciences at the University of Washington, a member of the National Academy of Sciences and co-Editor-in-Chief of the open access journal Epigenetics & Chromatin. In this episode we’re talking with Steve about his work, his approach to method development and refinement, and more.Links:Steven Henikoff protocols.io publications - https://www.protocols.io/researchers/steven-henikoff/protocolsHuman Cell Atlas - https://www.humancellatlas.org/CUT&Tag@home was recently chosen by the The Scientist as one of the top 5 technical advances of 2020 - https://www.the-scientist.com/news-opinion/top-technical-advances-of-2020-68297CUT&Tag@home - https://dx.doi.org/10.17504/protocols.io.bmbfk2jneLife article ‘Efficient chromatin accessibility mapping in situ by nucleosome-tethered tagmentation‘ - https://doi.org/10.7554/eLife.63274Jim Watson’s book “Molecular Biology of the Gene” - https://www.amazon.com/Molecular-Biology-Fifth-James-Watson/dp/080534635XNIH ENCODE Project - https://www.genome.gov/Funded-Programs-Projects/ENCODE-Project-ENCyclopedia-Of-DNA-Elements

Our “Innovation Conversations” series continues with our guest Dr. Claire Fraser, President of the American Association for the Advancement of Science (AAAS) and Director of the Institute for Genome Sciences at the University of Maryland School of Medicine. Sterne Kessler Director Trey Powers discussed several topics with Dr. Fraser including: her professional achievements and career challenges; bioprospecting in Yellowstone National Park; the importance of genome sequencing; perspectives on the U.S. patent system; and hopes for the future of biotech. Listen until the end of the episode to learn Dr. Fraser's favorite hobby, which involves two closets full of costumes! 

Ira Pastor, ideaXme life sciences ambassador and founder of Bioquark, interviews Dr. Matt Kaeberlein, Professor of Pathology, Adjunct Professor of Genome Sciences, and Adjunct Professor of Oral Health Sciences at the University of Washington.  Dr. Matt Kaeberlein's Cross Species Aging Research:  Dr. Matt Kaeberlein, is Professor of Pathology, Adjunct Professor of Genome Sciences, and Adjunct Professor of Oral Health Sciences at the University of Washington. With a PhD from MIT in Biology, and post-doctoral work in the Department of Genome Sciences, University of Washington, his research interests are focused on basic mechanisms of aging in order to facilitate translational interventions that promote healthspan and improve quality of life. Dr. Kaeberlein has published nearly 200 papers in top scientific journals and has been recognized by several prestigious awards, including a Breakthroughs in Gerontology Award, an Alzheimer’s Association Young Investigator Award, an Ellison Medical Foundation New Scholar in Aging Award, a Murdock Trust Award, a Pioneer in Aging Award, and the Vincent Cristofalo Rising Star in Aging Research. Dr. Kaeberlein's contributions have also been recognized with Fellow status in the American Association for the Advancement of Science, the American Aging Association, and the Gerontological Society of America. Dr. Kaeberlein is a past President of the American Aging Association and has served on their Executive Committee and Board of Directors since 2012. He has also served as a member of the Board of Directors for the Federation of American Societies for Experimental Biology and is currently the Chair of the Biological Sciences Section of the Gerontological Society of America. Dr. Kaeberlein serves on the editorial boards for several journals, including Science and eLife. Dr. Kaeberlein’s scientific discoveries have generated substantial public interest, with featured stories in major media outlets including appearing on the front page of the New York Times, the Today Show, CNN, the UK Telegraph, Popular Science, Time Magazine, Scientific American, NPR, USA Today, National Geographic, and many others. In addition to his primary appointments, Dr. Kaeberlein is the co-Director of the University of Washington Nathan Shock Center of Excellence in the Basic Biology of Aging, the founding Director of the Healthy Aging and Longevity Research Institute at the University of Washington, and founder and co-Director of the Dog Aging Project. On this episode we will hear from Dr. Kaeberlein about: His background and how he developed an interest in genomics, in biology, and in aging. His strategy in studying the "conserved" mechanisms of aging across organisms including yeast, nematodes, mice, and dogs. His studies with the drug Rapamycin in rejuvenating oral health in aging mice. His studies on the purification and analysis of nematode extracellular vesicles and their roles in studying the bio-markers of health and disease. His studies on systems biology in yeast to help illuminate mechanisms of personalized aging. His dog aging studies where he will be studying up to 10,000 dogs, in a 10-year effort aimed at tracking their health and identifying factors that can lengthen their lifespan. This interview is in American English Credits: Ira Pastor interview video, text, and audio. Follow Ira Pastor on Twitter: @IraSamuelPastor If you liked this interview, be sure to read this interview with Dr. Mark Wolff! Follow ideaXme on Twitter: @ideaxm On Instagram: @ideaxme On YouTube: ideaxme Find ideaXme across the internet including on iTunes, SoundCloud, Radio Public, TuneIn Radio, I Heart Radio, Google Podcasts, Spotify and more. ideaXme is a global podcast, creator series and mentor programme. Our mission: Move the human story forward!™ ideaXme Ltd.

Genetics is a growing part of health care, and  is used to identify heritable genetic variants that increase the risk of certain diseases and conditions, including some types of cancers. Among other things, learn why breast cancer-related variants are also related to prostate cancer, and why you should be leery of direct-to-consumer tests for heritable disease risk indicators. Guest: Gail P. Jarvik, MD, PhD, Endowed Chair in Medicine and Genome Sciences, and Professor and Head of Division of Medical Genetics, University of Washington, Seattle WA.

Can you influence how long you live and is there any molecules that extend lifespan? In today's episode Professor Matt Kaeberlein teach us about aging, how to affect aging and the interesting molecule Rapamycin. He also tells us about the dog aging project which focuses on understanding aging with the help of man's best friend. Please read more at: www.dogagingproject.org Dr. Matt Kaeberlein is a Professor of Pathology, Adjunct Professor of Genome Sciences, and Adjunct Professor of Oral Health Sciences at the University of Washington. His research interests are focused on basic mechanisms of aging in order to facilitate translational interventions that promote healthspan and improve quality of life. He has published more than 200 papers in top scientific journals.   For more episodes, inspiration and more, follow André at: Instagram: instagram.com/HealthPsychologyAndHumanNature Facebook: facebook.com/HealthPsychologyAndHumanNature Enjoy and have a terrific day.

Episode Summary: The gut microbiome is a hot topic these days but what about a city's microbiome? That is what Mariana Matus and her co-founder, Newsha Ghaeli have started to uncover! In this episode Rob and Matt chat with Mariana Matus, CEO and Co-Founder of Biobot.  Originally from Mexico City, Mariana settled in Boston after receiving her PhD in Computational Biology from MIT.  Inspired by their mutual interest in how technologies can improve cities and urban life, she and her co-founder, Newsha Ghaeli, started Biobot, which develops cutting-edge technology to transform sewers into public health observatories.  They are 1 of 2 teams doing this research within the US and 1 of 20 worldwide!  In this episode, learn more about their work, how it's transforming the public health sector, and hear Mariana's advice for first time entrepreneurs who have a science-based background.  Uncovered in this episode: How Biobot got started out of a MIT research project Biobot's success in reducing opioid overdoses within one city by 40% in six monthsWhat it was like to start a company in the US as two immigrant founders Challenges and opportunities inherent in selling to the government sectorThe benefits of having a co-founder and how important it has been in the process of building Biobot Biobot's experience coming out of Y combinator and how they are approaching their next raise The future of Biobot and their goals for helping cities across the US get ahead of infectious disease and drug abuse epidemics  List of resources mentioned in episode and suggested reading: Website: https://www.biobot.io/About Mariana: Dr. Matus leads technology development at Biobot Analytics. Through her PhD research, she specialized in the emerging field of wastewater-based epidemiology. Dr. Matus holds a PhD in Computational Biology from the Massachusetts Institute of Technology, Masters in Biotechnology from Wageningen University and Bachelors in Genome Sciences from the National Autonomous University of Mexico.  About Biobot: Biobot Analytics develops cutting-edge technology to transform sewers into public health observatories. Wastewater contains valuable information about the health of communities. We collect it. We analyze it. We tell you how to leverage it to make your city better.Our first product is to measure opioids and other drug metabolites in sewage to estimate consumption in cities. With this data, those working on harm reduction can assess the scope of the epidemic, allocate resources, and gauge the effectiveness of programming over time.  

It has been nearly two decades since scientists accomplished the first complete sequencing of the human genome. This historic moment gave us an unprecedented view of human DNA, the genetic code that determines everything from our eye color to our chance of disease, unlocking some of the biggest mysteries of human life. Twenty years later, despite the prevalence of genetic sequencing, considerable work remains to fulfill the promise of these advances to alleviate and cure human illness and disease. Scientists and researchers are “actually extremely good at reading genomes, but we're very, very bad at understanding what we're reading,” says Lea Starita, co-director of Brotman Baty Institute for Precision Medicine’s Advanced Technology Lab, and Research Assistant Professor in the Department of Genome Sciences at the University of Washington. But that is changing thanks to new tools and approaches, including one called Deep Mutational Scanning. This powerful technique for determining genetic variants is generating widespread interest in the field of genetics and personalized medicine, and it’s the subject of a symposium and workshop on Jan. 13 and 14, 2020, at the University of Washington. “I think approaches like Deep Mutational Scanning will eventually allow us to make better countermeasures, both vaccines and drugs that will help us combat even these viruses that are changing very rapidly” said Jesse Bloom, an evolutionary and computational biologist at the Fred Hutchinson Cancer Research Center, the Howard Hughes Medical Institute and the University of Washington Department of Genome Sciences. Bloom, who researches the evolution of viruses, will deliver the keynote at the symposium, held by the Brotman Baty Institute and the Center for the Multiplex Assessment of Phenotype. On this episode of the GeekWire Health Tech Podcast, we get a preview and a deeper understanding of Deep Mutational Scanning from Bloom and Starita.

I’m thrilled to have made friends with Dr. Amy Laura Hall. Not only is she back on the podcast to talk about Stanley Hauerwas’ influence on her work and theology, she’ll be our special guest in June at our annual live podcast at Annual Conference in Roanoke, Va. Amy Laura Hall was named a Henry Luce III Fellow in Theology for 2004-2005 and has received funding from the Lilly Foundation, the Josiah Trent Memorial Foundation, the American Theological Library Association, the Child in Religion and Ethics Project, the Pew Foundation and the Project on Lived Theology.At Duke University, Professor Hall has served on the steering committee of the Genome Ethics, Law, and Policy Center and as a faculty member for the FOCUS program of the Institute on Genome Sciences and Policy. She has served on the Duke Medical Center’s Institutional Review Board and as an ethics consultant to the V.A. Center in Durham. She served as a faculty adviser with the Duke Center for Civic Engagement (under Leela Prasad), on the Academic Council, and as a faculty advisor for the NCCU-Duke Program in African, African American & Diaspora Studies. She currently teaches with and serves on the faculty advisory board for Graduate Liberal Studies and serves as a core faculty member of the Focus Program in Global Health.Professor Hall was the 2017 Scholar in Residence at Foundry United Methodist Church in Washington D.C., served on the Bioethics Task Force of the United Methodist Church, and has spoken to academic and ecclesial groups across the U.S. and Europe. An ordained elder in the United Methodist Church, Hall is a member of the Rio Texas Annual Conference. She has served both urban and suburban parishes. Her service with the community includes an initiative called Labor Sabbath, an effort with the AFL-CIO of North Carolina to encourage congregations of faith to talk about the usefulness of labor unions, and, from August 2013 to June 2017, a monthly column for the Durham Herald-Sun. Professor Hall organized a conference against torture in 2011, entitled “Toward a Moral Consensus Against Torture,” and a “Conference Against the Use of Drones in Warfare” October 20-21, 2017. In collaboration with the North Carolina Council of Churches and the United Methodist Church, she organized a workshop with legal scholar Richard Rothstein held October, 2018.Amy Laura Hall is the author of four books: Kierkegaard and the Treachery of Love, Conceiving Parenthood: The Protestant Spirit of Biotechnological Reproduction, Writing Home with Love: Politics for Neighbors and Naysayers, and Laughing at the Devil: Seeing the World with Julian of Norwich. She has written numerous scholarly articles in theological and biomedical ethics. Recent articles include "The Single Individual in Ordinary Time: Theological Engagements in Sociobiology," which was a keynote lecture given with Kara Slade at the Society for the Study of Christian Ethics in 2012, and "Torture and American Television," which appeared in the April 2013 issue of Muslim World, a volume that Hall guest-edited with Daniel Arnold. Her essay “Love in Everything: A Brief Primer to Julian of Norwich" appeared in volume 32 of The Princeton Seminary Bulletin. Word and World published her essay on heroism in the Winter 2016 edition, and her essay "His Eye Is on the Sparrow: Collectivism and Human Significance" appeared in a volume entitled Why People Matter with Baker Publishing. Her forthcoming essays include a new piece on Kierkegaard and love for The T&T Clark Companion to the Theology of Kierkegaard, to be published by Bloomsbury T&T Clark.Laughing at the Devil was the focus of her 2018 Simpson Lecture at Simpson College in Iowa and has been chosen for the 2019 Virginia Festival of the Book. She continues work on a longer research project on masculinity and gender anxiety in mainstream, white evangelicalism.

I’m thrilled to have made friends with Dr. Amy Laura Hall. Not only is she back on the podcast to talk about Stanley Hauerwas’ influence on her work and theology, she’ll be our special guest in June at our annual live podcast at Annual Conference in Roanoke, Va. Amy Laura Hall was named a Henry Luce III Fellow in Theology for 2004-2005 and has received funding from the Lilly Foundation, the Josiah Trent Memorial Foundation, the American Theological Library Association, the Child in Religion and Ethics Project, the Pew Foundation and the Project on Lived Theology.At Duke University, Professor Hall has served on the steering committee of the Genome Ethics, Law, and Policy Center and as a faculty member for the FOCUS program of the Institute on Genome Sciences and Policy. She has served on the Duke Medical Center’s Institutional Review Board and as an ethics consultant to the V.A. Center in Durham. She served as a faculty adviser with the Duke Center for Civic Engagement (under Leela Prasad), on the Academic Council, and as a faculty advisor for the NCCU-Duke Program in African, African American & Diaspora Studies. She currently teaches with and serves on the faculty advisory board for Graduate Liberal Studies and serves as a core faculty member of the Focus Program in Global Health.Professor Hall was the 2017 Scholar in Residence at Foundry United Methodist Church in Washington D.C., served on the Bioethics Task Force of the United Methodist Church, and has spoken to academic and ecclesial groups across the U.S. and Europe. An ordained elder in the United Methodist Church, Hall is a member of the Rio Texas Annual Conference. She has served both urban and suburban parishes. Her service with the community includes an initiative called Labor Sabbath, an effort with the AFL-CIO of North Carolina to encourage congregations of faith to talk about the usefulness of labor unions, and, from August 2013 to June 2017, a monthly column for the Durham Herald-Sun. Professor Hall organized a conference against torture in 2011, entitled “Toward a Moral Consensus Against Torture,” and a “Conference Against the Use of Drones in Warfare” October 20-21, 2017. In collaboration with the North Carolina Council of Churches and the United Methodist Church, she organized a workshop with legal scholar Richard Rothstein held October, 2018.Amy Laura Hall is the author of four books: Kierkegaard and the Treachery of Love, Conceiving Parenthood: The Protestant Spirit of Biotechnological Reproduction, Writing Home with Love: Politics for Neighbors and Naysayers, and Laughing at the Devil: Seeing the World with Julian of Norwich. She has written numerous scholarly articles in theological and biomedical ethics. Recent articles include "The Single Individual in Ordinary Time: Theological Engagements in Sociobiology," which was a keynote lecture given with Kara Slade at the Society for the Study of Christian Ethics in 2012, and "Torture and American Television," which appeared in the April 2013 issue of Muslim World, a volume that Hall guest-edited with Daniel Arnold. Her essay “Love in Everything: A Brief Primer to Julian of Norwich" appeared in volume 32 of The Princeton Seminary Bulletin. Word and World published her essay on heroism in the Winter 2016 edition, and her essay "His Eye Is on the Sparrow: Collectivism and Human Significance" appeared in a volume entitled Why People Matter with Baker Publishing. Her forthcoming essays include a new piece on Kierkegaard and love for The T&T Clark Companion to the Theology of Kierkegaard, to be published by Bloomsbury T&T Clark.Laughing at the Devil was the focus of her 2018 Simpson Lecture at Simpson College in Iowa and has been chosen for the 2019 Virginia Festival of the Book. She continues work on a longer research project on masculinity and gender anxiety in mainstream, white evangelicalism.

Conor has, what he calls "microbiomania". Whatever the topic, he is able to bring it back to microbiomes in about 3 sentences. So imagine how excited he was to interview Colleen Cutcliffe, CEO of Pendulum whose mission is to make millions healthier through microbiome-targeted medical solutions. Another guest on this episode is Jacques Ravel, professor extraordinaire of The Human Microbiome and Women's Health at the Institute for Genome Sciences, University of Maryland. Enjoy ! (We sure did!) Interested in Conor's microbiomania? He writes regularly on his LinkedIn account. You can also read more Discovery Matters on our Medium publication. (with the same name).

Dr. Evan Eichler is Professor of Genome Sciences at the University of Washington. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. E.E. Eichler. Genetic Variation, Comparative Genomics, and the Diagnosis of Disease. N Engl J Med 2019;381:64-74.

Matt Kaeberlein – Longevity Expert Our guest today is Matt Kaeberlein, Ph.D., a globally recognized researcher and expert in the biology of aging. Dr. Kaeberlein’s research is based around the premise that understanding the molecular mechanisms of aging will lead to interventions that slow the onset and progression of age-related chronic conditions, such as cancer, diabetes, kidney disease, heart disease, Alzheimer’s and others. Dr. Kaeberlein received his Ph.D. from the Massachusetts Institute of Technology in 2002 advised by Leonard Guarente, and did his post-doctoral work with Stanley Fields in the Department of Genome Sciences at the University of Washington. Dr. Kaeberlein’s expertise in dietary restriction, longevity genes for therapeutics, aging in dogs, and Rapamycin really shines in this conversation. We were lucky enough to really explore his background while sharing our collective love of dogs. The conversation explores many areas, including: What is the difference between calories restriction and dietary restriction What are the biggest challenges with the science How Matt thinks about tailored dietary advice Why Matt launched the Dog Aging Project What we can learn from his research with dogs What is Rapamycin and why he’s so interested in its effects This conversation was incredibly illuminating and really fun. We hope you enjoy the episode and share it with your friends, family, and colleagues. About Matt Matt Kaeberlein Matt Kaeberlein Twitter Show Links Next Generation sequences Metabolomics Epigenetic clocks Calorie Restriction Society TAME Trial Rapamycin Daniel Promislow Dog Aging Project Acarbose NIA Interventions Testing Program Shock center of excellence George M. Martin Rapalog Everolimus

Women who are pregnant often talk how careful they are about what they eat and drink. They’re careful, points out Dr. Claire Fraser, because they’re feeding their baby. “Well, we should all think about diet in the same way that pregnant women do,” says Fraser. “Everything we put into our mouths, we’re either feeding or not feeding our gut microbes … And it’s important we keep our gut microbes happy.” Fraser is a pioneer and global leader in genomic medicine, a branch of molecular biology that focuses on the genome. In episode 32 of STEM-Talk, Fraser sits down with host Dawn Kernagis and IHMC founder Ken Ford to explain why we should all pay more attention to our guts, which is the home of more than 100 trillion bacteria. An endowed professor at the University of Maryland School of Medicine, Fraser is a founder and director of Maryland’s Institute for Genome Sciences. From 1998 to 2007, she was the director of the Institute for Genomic Research in Rockville, Maryland, and led teams that sequenced the genomes of several microbial organisms, including important human and animal pathogens. In 1995, she became the first person to map the complete genetic code of a free-living organism, Haemophilus Influenza, the bacterium that causes lower respiratory tract infections and meningitis in infants and young children. This discovery forever changed microbiology and launched a new field of study, microbial genomics. During this time, she and her team also sequenced the bacteria behind syphilis and Lyme disease, and eventually the first plant genome and the first human-pathogenic parasite. She even helped identify the source of a deadly 2001 anthrax attack in one of the biggest investigations conducted by U.S. law enforcement. Research into the benefits of gut bacteria has exploded around the world in the past decade.  In this STEM-Talk episode, Fraser explains the role these microbes play in improving health, preventing disease, and keeping us mentally sharp. She even shares how her diet has changed since she started studying the gut microbiome. Fraser also talks about working with the FBI during the 2001 antrhax attacks and her early work in microbiology that led to the first mapping of a free-living organism’s complete genetic code. Her recent lecture at IHMC, titled “The Human Gut Microbiome in Health and Disease,” can be viewed at ihmc.us/lectures. If you’re interested in learning more about the gut microbiome, Fraser in her lecture recommended “The Good Gut: Taking Control of Your Weight, Your Mood, and Your Long-term Health” by Stanford University scientists Justin and Erica Sonnenburg. 1:36: Dawn reads the five-star iTunes review titled “Intellectually Stimulating.” 2:28: Dawn and Ken provide a summary of Claire’s background and research, pointing out that she has authored more than 320 scientific publications, edited three books, and has served on committees of the National Science Foundation, Department of Energy, and National Institutes of Health. 4:13: Dawn welcomes Claire to STEM-Talk. 4:27: Claire talks about growing up in a suburb of Boston and taking her first biology course as a freshman in high school, which set her on a path toward a career in science. 5:37: Dawn asks Claire what led her to study microbiology. 6:53: Ken points out that there are more microbes on a person’s hand than there are people in the world. He asks Claire to give listeners a short intro into “Microbiome 101.” 9:34: Claire talks about the role of Lactobacillus rhamnosus GG (LGG), a strain of bacteria that is part of many popular probiotic products and has a reputation as a helpful microbe. 12:00: Ken asks Claire to expand upon the potential of probiotics and their usage in human beings. 14:56: Dawn points out that Claire is internationally known for her role in genome sequencing and asks what led Claire to establish the Institute of Genomics at Maryland.

Professor Elhanan Borenstein, University of Washington Associate Professor of Genome Sciences, will speak at the next Open Mic Science Night; Tuesday, March 7, 8 pm at the Treehouse Café. The title of his talk is ““Meet your inner microbial zoo: A genomic tour of your micro-biome” In this What's Up episode, BCB host Sonia Scaer talks with Professor Borenstein about his research.  He and his colleagues study the human microbiome and have developed sophisticated computational methods for analyzing microbiome data. Microbial species are a complex, highly diversified and largely uncharted communities. Each of us has a “normal” microbiome, containing a thousand different species of microorganisms. When an imbalance occurs  in our microbiome, it can lead to health problems. Because we can now manipulate the microbiome, we can affect human health. Professor Borenstein explains that its not enough to know what species are interacting with one another, and whether they are good or bad ones. Computational analysis is used to discover relationships within the complex system. In his talk at Open Mic Science, he will be discussing some of the new technologies used to understand the profiles of the microorganisms and how they interact with each other; research that has the potential to impact the treatment of human diseases. This is a fascinating field and sure to peak your interest on how your own microbiome affects your health. Credits: BCB host: Sonia Scaer; BCB tech Barry Peters; BCB audio editor and social media publisher: Diane Walker.

In this episode of Yoga | Birth | Babies, I had the opportunity to speak with microbiome scientist and mom, Anne M Estes, Phd. She enlightened me about the incredible world of microbiomes in relationship to a healthy pregnancy, birth and your newborn baby. Topics covered: What is microbiome and why is it important to consider? Pregnancy: What can effect the mother and baby’s microbiome during pregnancy? How the mother can change the microbiome in the vagina and gut? GBS, what it is, why it can be a problem and are there ways to manage it? Dispelling the whacky home remedies for GBS The effects of antibiotics on microbiome for GBS positive moms Labor and birth: The function of healthy vaginal microbiome play in delivery The benefits of the baby receiving the mother’s micro biome during a vaginal delivery The differences seen in terms of microbiome on the newborn with a baby born vaginally and one born cesarean Does the laboring process change the micro biome of the baby Seeding a baby who was born via c-section The bigger impact on society with 1/3 of babies being born via cesarean in terms of the micro biomes that they are not receiving How breastfeeding impacts baby’s gut and immune system The difference in the micro biome of breastfed babies to that of formula fed babies About Anne: Anne M. Estes, PhD is the human host of the microbiome blog, Mostly Microbes. As a microbiome scientist and mom, she is passionate about distilling the rapidly developing microbiome literature for parents, childbirth educators, and medical professionals so they can make informed medical and lifestyle decisions. Anne has two girls, ages 3 and 8, who inspire her to come up with creative ways to teach everyone about the amazing world of microbes. She is also a contributing blogger to the Lamaze International blog, Science and Sensibility, and MicroBE.net, an academic blog about the microbiome of built environments. She is also a postdoctoral fellow at the Institute for Genome Sciences in Baltimore, MD, where she studies how microbes and their animal hosts work together throughout host development. Learn more about your ad choices. Visit megaphone.fm/adchoices

Four events in one episode! I cover the NY Cytogenetics Regional Meeting I attending highlighting interesting points from presentations by Dr. Irene Cherric, Dr. Robert Hutchinson, Thomas Pope, Dr. Kazim R. Chohan, and Dr. Frank Middleton. I also discuss my presentation on the public's awareness of genetics through social media. These three genetic events are upcoming at UCONN/UCONN Health. All three have a focus on epigenetics, showing just how influential and universal this field of genetics is becoming. Environment, Epigenetics and Cancer: How to Cultivate the Connections October 24th, 2016 at 11:30 in the Student Union of UCONN Storrs, CT. Keynote Presentation by Mary Beth Terry, PhD “Breast Cancer Susceptibility : Rethinking the role of the environment and methods to improve risk assessment” Goal of the event to provide attendees with an update of current research and our understanding of the role of epigenetics and the environment in cancer risk and development. The panel will discuss advances in risk assessment, implications of scientific discoveries, epigenetic biomarkers and technological advances in screening, diagnosis and treatment of cancer as well as provide feedback about the public and patient perspective. Gene Editing: The CRISPR Revolution October 26th, 2016 at 6pm in the Dodd Research Center f UCONN Storrs, CT. Keynote speaker, Sharon Begley, the the senior science writer at STAT, the life sciences publication of the Boston Globe will be discussing the invention and evolution of the CRISPR-CAS9 technology. It seems as if the possibilities for CRISPR are endless: drought–resistant crops, disease resistant livestock, new drugs and a cure for cancer. How does this technology work? What are some of the current explorations of the gene editing technology? What are the limitations and the risks of its use? What ethical conversations need to be had by science, the public, policymakers? Prader-Willi Syndrome: New Epigenetic Findings and Potential Routes to Therap November 4th, 2016 at 2pm in the Henry B.C. Low, M.D. Learning Auditorium at UCONN Health in Farmington, CT. The keynote speaker will be Marc Lalande, Ph.D., Health Net Professor and Chairman from the Department of Genetics and Genome Sciences, UConn Health.

Welcome to another podcast brought to you by the AKC Canine Health Foundation. In this podcast we are speaking with Dr. Matt Kaeberlein, Associate Professor of Pathology at the University of Washington.  Dr. Kaeberlein discusses his groundbreaking work in aging and his interest in using pet dogs to evaluate a novel anti-aging compound. Dr. Kaeberlein completed his BS at Western Washington University in Seattle, followed by his PhD at Massachusetts Institute of Technology in Cambridge Massachusetts. He then completed a postdoctoral fellowship in the Department of Genome Sciences at the University of Washington that led to a faculty position within the Department of Pathology.   For more information on Dr. Kaeberline’s study, visit http://dogagingproject.com/. This podcast was made possible thanks to the generous support of the Kenneth A. Scott Charitable Trust, A KeyBank Trust.    

It's hard to imagine the twists and turns of evolution that gave rise to Homo Sapiens. After all, it required geologic time, and the existence of many long-gone species that were once close relatives. That may be one reason why – according to a recent poll – one-third of all Americans reject the theory of evolution. They prefer to believe that humans and other living organisms have existed in their current form since the beginning of time. But if you've ever been sick, you've been the victim of evolution on a very observable time scale. Nasty viruses and bacteria take full advantage of evolutionary forces to adapt to new hosts. And they can do it quickly. Discover how comparing the deadly 1918 flu virus with variants today may help us prevent the next pandemic. Also, while antibiotic resistance is threatening to become a major health crisis, better understanding of how bacteria evolve their defenses against our drugs may help us out. And the geneticist who sequenced the Neanderthal genome says yes, our hirsute neighbors co-mingled with humans. It's Skeptic Check … but don't take our word for it! Guests: •  Svante Pääbo – Evolutionary geneticist, Max Planck Institute for Evolutionary Anthropology, author of Neanderthal Man: In Search of Lost Genomes •  Ann Reid – – Molecular biologist, executive director of the National Center for Science Education, Oakland, California •  Martin Blaser – Microbiologist, New York University School of Medicine, member of the National Academy of Sciences, author of Missing Microbes: How the Overuse of Antibiotics Is Fueling Our Modern Plagues •  Gautam Dantas – Pathologist, immunologist, Center for Genome Sciences and Systems Biology, Washington University, Saint Louis First released March 31, 2014. Learn more about your ad choices. Visit megaphone.fm/adchoices

ENCORE It’s hard to imagine the twists and turns of evolution that gave rise to Homo Sapiens. After all, it required geologic time, and the existence of many long-gone species that were once close relatives. That may be one reason why – according to a recent poll – one-third of all Americans reject the theory of evolution. They prefer to believe that humans and other living organisms have existed in their current form since the beginning of time.       But if you’ve ever been sick, you’ve been the victim of evolution on a very observable time scale. Nasty viruses and bacteria take full advantage of evolutionary forces to adapt to new hosts. And they can do it quickly. Discover how comparing the deadly 1918 flu virus with variants today may help us prevent the next pandemic. Also, while antibiotic resistance is threatening to become a major health crisis, better understanding of how bacteria evolve their defenses against our drugs may help us out. And the geneticist who sequenced the Neanderthal genome says yes, our hirsute neighbors co-mingled with humans. It’s Skeptic Check … but don’t take our word for it! Guests: •   Svante Pääbo – Evolutionary geneticist, Max Planck Institute for Evolutionary Anthropology, author of Neanderthal Man: In Search of Lost Genomes •   Ann Reid – – Molecular biologist, executive director of the National Center for Science Education, Oakland, California •   Martin Blaser – Microbiologist, New York University School of Medicine, member of the National Academy of Sciences, author of Missing Microbes: How the Overuse of Antibiotics Is Fueling Our Modern Plagues •   Gautam Dantas – Pathologist, immunologist, Center for Genome Sciences and Systems Biology, Washington University, Saint Louis First released March 31, 2014.

The discussion of "designer babies" often revolves around gender or hair color, but as Nita Farahany and Marcy Darnovsky explore, the medical debate is far more complicated. Farahany is Professor of Law and Philosophy, Director of Institute for Genome Sciences and Policy, Duke University; Member, Presidential Commission for the Study of Bioethical Issues. Should we screen embryos for disease? Should we make genetic modifications? These considerations raise ethical concerns and call into question the validity of surrounding research. The lack of regulation and oversight make this particular biotechnology frightening to some, while the potential for disease eradicating techniques excites others. But how far is too far? What are the major scientific and ethical hurdles to assuage the skeptics? Marcy Darnovsky is the executive director of the Center for Genetics and Society. Nita Farahany is professor of Law and Philosophy and director of the Institute for Genome Sciences and Policy at Duke University. She is a member of the Presidential Commission for the Study of Bioethical Issues.

Evan Eichler is an Associate Professor of Genome Sciences at the University of Washington. The long-term goal of his research is to understand the evolution, pathology and mechanisms of recent gene duplication and DNA transposition within the human genome. Series: "CARTA - Center for Academic Research and Training in Anthropogeny" [Science] [Show ID: 21982]

Evan Eichler is an Associate Professor of Genome Sciences at the University of Washington. The long-term goal of his research is to understand the evolution, pathology and mechanisms of recent gene duplication and DNA transposition within the human genome. Series: "CARTA - Center for Academic Research and Training in Anthropogeny" [Science] [Show ID: 21982]

http://www.StockMarketFunding.com Human Genome Sciences Lupus Drug FDA Program Schedule Assuming the Worst Market Manipulation? Wall St is hyping the suicidal results. We believe today's "pre market" manipulation in price action caused some large institutions to take a short position going into the move and the FDA Program Schedule Released at 8 AM today did not show any meaningful new data. Premarket high was $29.50 and now we're trading at $24.50 $5 dollars lower. The new breakthrough in Human Genome Sciences Benlysta drug approval for lupus patients. SMF will cover the pros and the cons of the HGSI new drug and benefits to humanity. We will take a look at one of the most positive developments in "biotechnology" in the past 50 years. We have highlighted HGSI and the longer term trends relative to the current drug developments. BENLYSTA is an investigational human monoclonal antibody drug. It is the first in a new class of drugs called BLyS-specific inhibitors that recognize and inhibit the biological activity of B-lymphocyte stimulator, or BLyS, which was discovered by HGS in 1996. We and GlaxoSmithKline (GSK) are developing BENLYSTA under a co-development and commercialization agreement entered into in 2006. In lupus, rheumatoid arthritis and certain other autoimmune diseases, elevated levels of BLyS are believed to contribute to the production of autoantibodies – antibodies that attack and destroy the body’s own healthy tissues.BENLYSTA has successfully met its primary endpoint in two pivotal Phase 3 trials in seropositive patients with systemic lupus erythematosus (SLE). In June 2010, HGS and GSK submitted regulatory applications seeking approval to market BENLYSTA in the United States and Europe. The FDA has granted BENLYSTA a priority review designation with a Prescription Drug User Fee Act (PDUFA) target date of December 9, 2010 – so it is possible that BENLYSTA could receive regulatory approval in the United States before the end of 2010.

http://www.StockMarketFunding.com Human Genome Sciences Lupus Drug FDA Program Schedule Assuming the Worst Market Manipulation? Wall St is hyping the suicidal results. We believe today's "pre market" manipulation in price action caused some large institutions to take a short position going into the move and the FDA Program Schedule Released at 8 AM today did not show any meaningful new data. Premarket high was $29.50 and now we're trading at $24.50 $5 dollars lower. The new breakthrough in Human Genome Sciences Benlysta drug approval for lupus patients. SMF will cover the pros and the cons of the HGSI new drug and benefits to humanity. We will take a look at one of the most positive developments in "biotechnology" in the past 50 years. We have highlighted HGSI and the longer term trends relative to the current drug developments. BENLYSTA is an investigational human monoclonal antibody drug. It is the first in a new class of drugs called BLyS-specific inhibitors that recognize and inhibit the biological activity of B-lymphocyte stimulator, or BLyS, which was discovered by HGS in 1996. We and GlaxoSmithKline (GSK) are developing BENLYSTA under a co-development and commercialization agreement entered into in 2006. In lupus, rheumatoid arthritis and certain other autoimmune diseases, elevated levels of BLyS are believed to contribute to the production of autoantibodies – antibodies that attack and destroy the body’s own healthy tissues.BENLYSTA has successfully met its primary endpoint in two pivotal Phase 3 trials in seropositive patients with systemic lupus erythematosus (SLE). In June 2010, HGS and GSK submitted regulatory applications seeking approval to market BENLYSTA in the United States and Europe. The FDA has granted BENLYSTA a priority review designation with a Prescription Drug User Fee Act (PDUFA) target date of December 9, 2010 – so it is possible that BENLYSTA could receive regulatory approval in the United States before the end of 2010.

New Break through in Human Genome Sciences Benlysta drug approval for lupus patients. SMF will cover the pros and the cons of the HGSI new drug and benefits to humanity. We will take a look at one of the most positive developments in "biotechnology" in the past 50 years. We have highlighted HGSI and the longer term trends relative to the current drug developments. BENLYSTA is an investigational human monoclonal antibody drug. It is the first in a new class of drugs called BLyS-specific inhibitors that recognize and inhibit the biological activity of B-lymphocyte stimulator, or BLyS, which was discovered by HGS in 1996. We and GlaxoSmithKline (GSK) are developing BENLYSTA under a co-development and commercialization agreement entered into in 2006. In lupus, rheumatoid arthritis and certain other autoimmune diseases, elevated levels of BLyS are believed to contribute to the production of autoantibodies – antibodies that attack and destroy the body’s own healthy tissues.BENLYSTA has successfully met its primary endpoint in two pivotal Phase 3 trials in seropositive patients with systemic lupus erythematosus (SLE). In June 2010, HGS and GSK submitted regulatory applications seeking approval to market BENLYSTA in the United States and Europe. The FDA has granted BENLYSTA a priority review designation with a Prescription Drug User Fee Act (PDUFA) target date of December 9, 2010 – so it is possible that BENLYSTA could receive regulatory approval in the United States before the end of 2010.

New Break through in Human Genome Sciences Benlysta drug approval for lupus patients. SMF will cover the pros and the cons of the HGSI new drug and benefits to humanity. We will take a look at one of the most positive developments in "biotechnology" in the past 50 years. We have highlighted HGSI and the longer term trends relative to the current drug developments. BENLYSTA is an investigational human monoclonal antibody drug. It is the first in a new class of drugs called BLyS-specific inhibitors that recognize and inhibit the biological activity of B-lymphocyte stimulator, or BLyS, which was discovered by HGS in 1996. We and GlaxoSmithKline (GSK) are developing BENLYSTA under a co-development and commercialization agreement entered into in 2006. In lupus, rheumatoid arthritis and certain other autoimmune diseases, elevated levels of BLyS are believed to contribute to the production of autoantibodies – antibodies that attack and destroy the body’s own healthy tissues.BENLYSTA has successfully met its primary endpoint in two pivotal Phase 3 trials in seropositive patients with systemic lupus erythematosus (SLE). In June 2010, HGS and GSK submitted regulatory applications seeking approval to market BENLYSTA in the United States and Europe. The FDA has granted BENLYSTA a priority review designation with a Prescription Drug User Fee Act (PDUFA) target date of December 9, 2010 – so it is possible that BENLYSTA could receive regulatory approval in the United States before the end of 2010.

Evan Eichler, University of Washington Professor of Genome Sciences explores large-scale variation in human genomic DNA that contributes to primate gene evolution. Series: "CARTA - Center for Academic Research and Training in Anthropogeny" [Science] [Show ID: 18705]

Evan Eichler, University of Washington Professor of Genome Sciences explores large-scale variation in human genomic DNA that contributes to primate gene evolution. Series: "CARTA - Center for Academic Research and Training in Anthropogeny" [Science] [Show ID: 18705]

Host: Janet Wright, MD Guest: Geoffrey Ginsburg, MD, PhD Patient-centered care is a hot topic in health care these days, though usually when we think of patient-centeredness, our thinking tilts toward aspects of policymaking or system delivery. Host Dr. Janet Wright takes a look at the science side of patient-centered care — the more precise tailoring of therapy known as personalized medicine — with Dr. Geoffrey Ginsburg, founding director of the Center for Genomic Medicine at the Duke Institute for Genome Sciences and Policy and professor of medicine and pathology at Duke University School of Medicine. Dr. Ginsburg also shares what he considers to be the top priorities of this field, forging a path from the research to clinical care. How might personalized medicine impact cardiovascular care in the years to come?

Host: Janet Wright, MD Guest: Geoffrey Ginsburg, MD, PhD Patient-centered care is a hot topic in health care these days, though usually when we think of patient-centeredness, our thinking tilts toward aspects of policymaking or system delivery. Host Dr. Janet Wright takes a look at the science side of patient-centered care — the more precise tailoring of therapy known as personalized medicine — with Dr. Geoffrey Ginsburg, founding director of the Center for Genomic Medicine at the Duke Institute for Genome Sciences and Policy and professor of medicine and pathology at Duke University School of Medicine. Dr. Ginsburg also shares what he considers to be the top priorities of this field, forging a path from the research to clinical care. How might personalized medicine impact cardiovascular care in the years to come?

Professor of Genome Sciences and of Medicine, Dr. Maynard Olson delivers his 2003 lecture, companion piece to the Francis S. Collins lecture The Genome and Your Future.

Professor of Genome Sciences and of Medicine, Dr. Maynard Olson delivers his 2003 lecture, companion piece to the Francis S. Collins lecture The Genome and Your Future.

Dr. Misha Angrist, Assistant Professor of the Practice at the Duke University Institute for Genome Sciences & Policy